| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
Like other fluoroquinolones, (R,R)‑BAY‑Y 3118 targets bacterial type II topoisomerases, specifically DNA gyrase (GyrA/GyrB) and topoisomerase IV (ParC/ParE). It is believed to bind to the enzyme‑DNA complex, stabilizing DNA double‑strand breaks and leading to bacterial cell death. However, the R‑enantiomer binds with lower affinity and/or altered orientation compared to the active S‑enantiomer.
|
|---|---|
| ln Vitro |
For Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis, (R,R)-BAY-Y 3118 demonstrates bactericidal activity ranging from a log 1/C 5.65-7.47[1].
In vitro, (R,R)-BAY-Y 3118 shows bactericidal activity ranging from log 1/C 5.65-7.47 against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Enterococcus faecalis. The compound also induces damage to mitochondrial DNA (mtDNA) in eukaryotic cells, consistent with the known off‑target activity of quinolones on eukaryotic topoisomerase II. However, its activity is significantly weaker than the parent compound BAY‑Y 3118 or the S‑enantiomer. |
| ln Vivo |
In vivo animal activity for (R,R)-BAY-Y 3118 has not been formally evaluated. Based on the pharmacokinetic and pharmacodynamic profile of fluoroquinolones, the R‑enantiomer is expected to have limited in vivo efficacy due to its weak bactericidal activity. The racemic BAY‑Y 3118 or the S‑enantiomer would be the preferred candidates for any in vivo infection model.
|
| Enzyme Assay |
Non‑cellular enzyme inhibition assays are performed using purified DNA gyrase (E. coli) or topoisomerase IV. The enzyme is incubated with relaxed pBR322 DNA in the presence of ATP and varying concentrations of (R,R)-BAY-Y 3118 (0.01-100 microM) for 30 min at 37 degC. The reaction is quenched with SDS/proteinase K, and DNA products are resolved by agarose gel electrophoresis. The IC50 for supercoiling inhibition (gyrase) or decatenation (topo IV) is determined by densitometric analysis.
|
| Cell Assay |
The minimum inhibitory concentration (MIC) of (R,R)-BAY-Y 3118 is determined via broth microdilution according to CLSI guidelines. Bacterial strains are cultured overnight, diluted to 5 × 10⁵ CFU/mL in cation‑adjusted Mueller‑Hinton broth, and incubated with serial twofold dilutions of the compound (0.125-64 microg/mL) for 18-20 h at 37 degC. MIC is defined as the lowest concentration that inhibits visible growth. For eukaryotic cell toxicity, HepG2 or Vero cells are treated with (R,R)-BAY-Y 3118 (0.1-100 microM) and mitochondrial DNA integrity is assessed by Southern blot or qPCR.
|
| Animal Protocol |
In vivo efficacy studies with (R,R)-BAY-Y 3118 have not been published. For the racemic mixture or S‑enantiomer of BAY‑Y 3118, a mouse septicemia model (e.g., intraperitoneal injection of 5 × 10⁷ CFU of E. coli) could be used. The test compound (1-30 mg/kg) is administered subcutaneously or orally 1 h post‑infection. Survival is monitored for 7 days, and bacterial counts in blood are determined. For the R‑enantiomer, a high dose would likely be required to achieve any efficacy.
|
| ADME/Pharmacokinetics |
Formal PK studies specifically for (R,R)-BAY-Y 3118 have not been reported. As a fluoroquinolone, it is expected to have high oral bioavailability (70-90%) and a moderate plasma half‑life (3-6 h) in rodents, with good tissue penetration. The R‑enantiomer may exhibit similar PK properties but with reduced target affinity and therefore lower overall antibacterial efficacy.
|
| Toxicity/Toxicokinetics |
Toxicological data specific to (R,R)-BAY-Y 3118 are not available. However, the racemate BAY‑Y 3118 has been reported to damage mitochondrial DNA in embryonic turkey liver cells, a known off‑target effect of quinolones that is associated with potential hepatotoxicity. For the R‑enantiomer, toxicities are expected to be similar but may require higher doses to manifest.
|
| References |
[1]. Cianchetta G, et al. Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach. J Med Chem. 2004;47(12):3193-3201.
|
| Additional Infomation |
(R,R)-BAY-Y 3118 is a research‑grade chemical tool used to study the stereoselectivity of fluoroquinolone antibacterial activity and the relationship between chirality, target binding, and toxicity. It has not been developed as a therapeutic agent, has not entered clinical trials, and is not approved for human or veterinary use. The parent compound BAY‑Y 3118 (racemate) is an investigational fluoroquinolone that did not advance to market.
|
| Molecular Formula |
C20H21CLFN3O3
|
|---|---|
| Molecular Weight |
405.85
|
| Exact Mass |
405.125
|
| CAS # |
151213-22-8
|
| Related CAS # |
BAY-Y 3118;151213-16-0
|
| PubChem CID |
44338422
|
| Appearance |
White to light yellow solid powder
|
| LogP |
1.3
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
28
|
| Complexity |
715
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1C[C@@H]2CN(C[C@@H]2NC1)C3=C(C=C4C(=C3Cl)N(C=C(C4=O)C(=O)O)C5CC5)F
|
| InChi Key |
VRXORHRXNRJZCQ-BMIGLBTASA-N
|
| InChi Code |
InChI=1S/C20H21ClFN3O3/c21-16-17-12(19(26)13(20(27)28)8-25(17)11-3-4-11)6-14(22)18(16)24-7-10-2-1-5-23-15(10)9-24/h6,8,10-11,15,23H,1-5,7,9H2,(H,27,28)/t10-,15+/m1/s1
|
| Chemical Name |
7-[(4aR,7aR)-1,2,3,4,4a,5,7,7a-octahydropyrrolo[3,4-b]pyridin-6-yl]-8-chloro-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4640 mL | 12.3198 mL | 24.6396 mL | |
| 5 mM | 0.4928 mL | 2.4640 mL | 4.9279 mL | |
| 10 mM | 0.2464 mL | 1.2320 mL | 2.4640 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
